- Home
- Equipment
- usa north carolina
- cancer systemic therapy
Show results for
Refine by
Cancer Systemic Therapy Equipment Supplied In Usa North Carolina
5 equipment items found
Manufactured by:XILIS, Inc. based inDurham, NORTH CAROLINA (USA)
Xilis’ MicroOrganoSphereTM powers the only assay which can provide oncologists with accurate results of drug sensitivity on a patient’s own tumor within the clinical decision-making window - finally realizing the promise of precision medicine. Xilis is developing a panel of disease specific assays systematically testing the most important standard-of-care drugs within equipoise or ...
Manufactured by:RedHill Biopharma Ltd. based inTel-Aviv, ISRAEL
RHB-107 (INN: upamostat) (formerly MESUPRON) is a first-in-class, once-daily, orally-administered, potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases. ...
Manufactured by:GeneCentric Therapeutics, Inc. based inDurham, NORTH CAROLINA (USA)
Pancreatic Cancer is the 11th most common cancer type with an estimated 55,000 new cases in the US in 2018, according to the United States National Cancer Institute. While it represents three percent of all cancers, pancreatic cancer is one of the most lethal as it is so difficult to detect in early stages, accounting for seven percent of all cancer deaths and carrying among the lowest five ...
by:NeoGenomics Laboratories based inFort Myers, FLORIDA (USA)
RaDaR™ is a personalized, multi-tumor liquid biopsy assay that can track a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity. This allows RaDaR™ to detect traces of molecular residual disease (MRD) in a patient following surgery or other treatment for cancer, enabling early detection of relapse and accurate monitoring. ...
Manufactured by:RedHill Biopharma Ltd. based inTel-Aviv, ISRAEL
MOVANTIK is the leading Peripherally-Acting Mu-Receptor Opioid antagonist (PAMORA) indicated for the treatment of opioid induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage ...